Pharmaceutical

Health Canada approves Acadia’s DAYBUE for Rett syndrome

Acadia Pharmaceuticals has received marketing authorisation from Health Canada for DAYBUE (trofinetide) to treat Rett syndrome.

Oct 18, 2024 - 04:00
Health Canada approves Acadia’s DAYBUE for Rett syndrome
Acadia Pharmaceuticals has received marketing authorisation from Health Canada for DAYBUE (trofinetide) to treat Rett syndrome.
Read the original article

Tags:

Previous Article

Glaukos eyes FDA approval for ocular therapy after Phase III win

Next Article

Lexicon partners Viatris for global expansion of sotagliflozin

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Harvard longevity scientist sparks furor with claim about reversing aging in dogs

STAT+: Harvard longevity scientist sparks furor with cl...

Mar 6, 2024

Risk adjusted net present value: What is the current va...

Nov 18, 2023

Opinion: STAT+: Dana-Farber CEO Laurie Glimcher has always been a trailblazer and a risk taker

Opinion: STAT+: Dana-Farber CEO Laurie Glimcher has alw...

Dec 11, 2023